Loading...
NASDAQ: GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
●S&P 500 since 2004
Market Cap
$175.40B
52w High
$157.29
52w Low
$93.37
P/E
20.62
Volume
6.80M
Outstanding Shares
1.24B
Company profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
CEODaniel O'Day
SectorHealthcare
IndustryDrug Manufacturers - General
Employees17,600
IPO dateJan 22, 1992
Valuation
Forward P/E—
EV/EBITDA15.69
Enterprise value$169.72B
Stock splits
Jan 28, 20132:1
Jun 25, 20072:1
Sep 7, 20042:1
Mar 8, 20022:1
Feb 22, 20012:1
Profitability & growth
Revenue growth4.7%
Gross margin80.8%▲10.77%vs FY2024
Operating margin37.37%▲594.37%vs FY2024
ROE37.62%▲1415.19%vs FY2024
Analyst consensus
RatingBuy
Target price$158.71▲12.33%
37
Buy
20
Hold
1
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 23, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.01
$1.96
Q3FY25
ActualEst.
$2.47
$2.13
Q4FY25
ActualEst.
$1.86
$1.81
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$7.08B
$6.98B
Q3FY25
ActualEst.
$7.77B
$7.45B
Q4FY25
ActualEst.
$7.93B
$7.69B
Q1FY26
Next Est.
—